In Reply: Both letters correctly point to heterogeneity in the “Fatal and nonfatal MI” classification in the Table in our Commentary. Because the cited ADVANCE and PROACTIVE publications did not provide the fatal and nonfatal MI incidence rates, in the Table we instead used nonfatal MI incidence for those 2 studies, but this was unfortunately not made clear. In addition, in the control group for the ADVANCE trial, the MI rate should have been 5.6 rather than 5.5. A correction appears in this issue of JAMA.
Psaty BM, Prentice RL. Event Rates in Trials of Patients With Type 2 Diabetes—Reply. JAMA. 2010;303(8):732-733. doi:10.1001/jama.2010.139